Clinical trials: Silodosin
Benign Prostatic Hypertrophy
Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH
Korea has newly adopted 8mg Silodosin once daily. Against these backdrops, this clinical study is designed to demonstrate that the newly adopted dose is not inferior to the existing dose in its efficacy and safety.
- Trial name
- NCT01260129
- Testing
- Silodosin
- Where
- 14 sites in South Korea
- Volunteers
- 424 people
- Sponsor
- JW Pharmaceutical
Benign Prostatic Hyperplasia
Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)
This clinical study is designed to evaluate the efficacy and safety of silodosin in a 12 week treatment of patients with severe urinary disorders associated with benign prostatic hyperplasia (BPH).
- Trial name
- STRONG (NCT01259531)
- Testing
- Silodosin
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- JW Pharmaceutical
Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia
This is a randomized, double-blind, controlled, non-inferiority multicenter Phase III clinical study to evaluate the efficacy and safety of H077 sustained-release tablets versus silodosin capsules in treating benign prostatic…
- Trial name
- NCT07146386
- Testing
- H077 sustained-release tablet, Silodosin capsules Control Group
- Where
- 66 sites in China
- Volunteers
- 728 people
- Sponsor
- Shanghai Huilun Pharmaceutical Co., Ltd.
Neurogenic Bladder, Voiding Dysfunction
Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder
Because the bladder neck and proximal urethra contain abundant α1-adrenergic receptors, α-blockers or α1-blockers are well-known to reduce bladder neck obstruction in patients with or without neurogenic bladder.
- Trial name
- NCT01228370
- Testing
- silodosin
- Where
- 6 sites in South Korea
- Volunteers
- 95 people
- Sponsor
- JW Pharmaceutical
Nocturia, Benign Prostatic Hyperplasia
Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia
The objective of this study is to determine safety and efficacy of silodosin, which is a treatment for benign prostatic hyperplasia with high selectivity to α1A-receptor, on patients with benign prostatic hyperplasia accompanied…
- Trial name
- BPH (NCT02106182)
- Testing
- Silodosin, Laboratory tests, 3-days voiding diary
- Where
- 6 sites in South Korea
- Volunteers
- 135 people
- Sponsor
- JW Pharmaceutical
BPH (Benign Prostatic Hyperplasia)
The Efficacy and Safety of Qianweitai (Silodosin Capsule) Versus Tamsulosin in the Treatment of BPH
The goal of this clinical trial is to learn if Qianweitai (QWT, silodosin capsule) works to treat BPH/LUTS in male adults. It will also learn the safety about QWT. The main questions it aims to answer are: 1.
- Trial name
- NCT07134907
- Testing
- Silodosin, Tamsolusin
- Where
- 6 sites in China
- Volunteers
- 110 people
- Sponsor
- Shanghai Huilun Pharmaceutical Co., Ltd.
Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
The Efficacy and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia
Objective: To evaluate the efficacy and safety of Silodosin Capsules in the treatment of Benign Prostatic Hyperplasia (BPH) with Lower Urinary Tract Symptoms (LUTS) compared with Tamsulosin Hydrochloride Sustained Release…
- Trial name
- NCT05551221
- Testing
- Silodosin Capsules, Tamsulosin
- Where
- 8 sites in China
- Volunteers
- 110 people
- Sponsor
- Xintian Pharmaceutical
Urinary Calculus
A Dose-finding Study of Silodosin in Patients With Urinary Calculi
The purpose of this study is to evaluate the efficacy and the safety of silodosin in urinary calculi patients.
- Trial name
- NCT01539265
- Testing
- silodosin
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Ureteric Stone of Lower Third of Ureter
Medical Stone Expulsive Therapy for Acutely Obstructed Ureteric Calculi
As a first treatment option for small-size ureteric stones, α-blockers are now being used for medical expulsive therapy (MET) instead of invasive procedures.
- Trial name
- NCT05977647
- Testing
- Tamsulosin Oral Capsule
- Where
- Pakistan
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Getz Pharma
Ureteral Stone
Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones
A lower ureteral calculus, which measures 5 millimeters and less, may be easily expelled by symptomatic therapy. Actually, it has about a 50% chance of successful expulsion.
- Trial name
- STONE (NCT01533389)
- Testing
- Silodosin
- Where
- 5 sites in South Korea
- Volunteers
- 114 people
- Sponsor
- JW Pharmaceutical
Ureteral Calculi, Kidney Stones
Study of Silodosin to Facilitate Passage of Urinary Stones
The purpose of this study is to assess if patients treated with silodosin will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.
- Conditions
- Ureteral Calculi, Kidney Stones, Urolithiasis
- Trial name
- NCT01144949
- Testing
- silodosin
- Where
- 27 sites in United States
- Volunteers
- 239 people
- Sponsor
- Watson Pharmaceuticals
Nocturia, Prostatic Hyperplasia
A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia
Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH
- Trial name
- NCT00793819
- Testing
- silodosin
- Where
- 27 sites in United States
- Volunteers
- 215 people
- Sponsor
- Watson Pharmaceuticals
Benign Prostatic Hyperplasia
Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia
The purpose of this study is to confirm in a larger population in Europe the effectiveness and safety observed with silodosin in previous clinical trials.
- Trial name
- SiRE (NCT01757769)
- Testing
- Silodosin
- Where
- Italy
- Volunteers
- 1,036 people
- Sponsor
- RECORDATI GROUP
Benign Prostatic Hyperplasia
Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH
A new drug for the treatment of benign prostatic hyperplasia is compared with placebo and tamsulosin (a drug belonging to the same therapeutic class) for to determine if it is safe and effective (the first phase of the study…
- Trial name
- NCT00359905
- Testing
- Silodosin, Tamsulosin
- Where
- United Kingdom
- Volunteers
- 1,228 people
- Sponsor
- RECORDATI GROUP
Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
The primary objective is to compare the efficacy of silodosin 4 and 8 mg once daily with placebo in the treatment of subjects with moderate to severe abacterial chronic prostatitis/chronic pelvic pain syndrome during a 12 week…
- Trial name
- NCT00740779
- Testing
- Silodosin 8 mg, Silodosin 4 mg
- Where
- 22 sites in United States
- Volunteers
- 153 people
- Sponsor
- Watson Pharmaceuticals